Executive summary of the American Radium Society on appropriate use criteria for nonoperative management of rectal adenocarcinoma: Systematic review and guidelines Review


Authors: Anker, C. J.; Tchelebi, L. T.; Selfridge, J. E.; Jabbour, S. K.; Akselrod, D.; Cataldo, P.; Abood, G.; Berlin, J.; Hallemeier, C. L.; Jethwa, K. R.; Kim, E.; Kennedy, T.; Lee, P.; Sharma, N.; Small, W. Jr; Williams, V. M.; Russo, S.
Review Title: Executive summary of the American Radium Society on appropriate use criteria for nonoperative management of rectal adenocarcinoma: Systematic review and guidelines
Abstract: For patients with rectal cancer, the standard approach of chemotherapy, radiation therapy, and surgery (trimodality therapy) is associated with significant long-term toxicity and/or colostomy for most patients. Patient options focused on quality of life (QOL) have dramatically improved, but there remains limited guidance regarding comparative effectiveness. This systematic review and associated guidelines evaluate how various treatment strategies compare to each other in terms of oncologic outcomes and QOL. Cochrane and Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) methodology were used to search for prospective and retrospective trials and meta-analyses of adequate quality within the Ovid Medline database between January 1, 2012, and June 15, 2023. These studies informed the expert panel, which rated the appropriateness of various treatments in 6 clinical scenarios through a well-established consensus methodology (modified Delphi). The search process yielded 197 articles that advised voting. Increasing data have shown that nonoperative management (NOM) and primary surgery result in QOL benefits noted over trimodality therapy without detriment to oncologic outcomes. For patients with rectal cancer for whom total mesorectal excision would result in permanent colostomy or inadequate bowel continence, NOM was strongly recommended as usually appropriate. Restaging with tumor response assessment approximately 8 to 12 weeks after completion of radiation therapy/chemoradiation therapy was deemed a necessary component of NOM. The panel recommended active surveillance in the setting of a near-complete or complete response. In the setting of NOM, 54 to 56 Gy in 27 to 31 fractions concurrent with chemotherapy and followed by consolidation chemotherapy was recommended. The panel strongly recommends primary surgery as usually appropriate for a T3N0 high rectal tumor for which low anterior resection and adequate bowel function is possible, with adjuvant chemotherapy considered if N+. Recent data support NOM and primary surgery as important options that should be offered to eligible patients. Considering the complexity of multidisciplinary management, patients should be discussed in a multidisciplinary setting, and therapy should be tailored to individual patient goals/values. © 2024 Elsevier Inc.
Keywords: cancer chemotherapy; overall survival; review; fluorouracil; multimodality cancer therapy; united states; capecitabine; cancer radiotherapy; disease free survival; combined modality therapy; chemotherapy; antineoplastic agent; adenocarcinoma; cancer immunotherapy; quality of life; radiotherapy; practice guideline; pathology; societies, medical; tumors; systematic review; radiation dose fractionation; conservative treatment; active surveillance; folinic acid; mismatch repair; microsatellite instability; medical society; brachytherapy; surgery; external beam radiotherapy; oxaliplatin; rectal neoplasms; intestine function; rectum tumor; therapy; diseases; induction chemotherapy; rectal cancer; meta-analysis; colostomy; total mesorectal excision; rectal adenocarcinoma; comparative effectiveness; expert panels; radium; immune checkpoint inhibitor; medline database; consolidation chemotherapy; capecitabine plus oxaliplatin; humans; human; male; female; circulating tumor dna; anus continence; prospectives; sintilimab; dostarlimab; search process
Journal Title: International Journal of Radiation Oncology, Biology, Physics
Volume: 120
Issue: 4
ISSN: 0360-3016
Publisher: Elsevier Inc.  
Date Published: 2024-11-15
Start Page: 946
End Page: 977
Language: English
DOI: 10.1016/j.ijrobp.2024.05.019
PUBMED: 38797496
PROVIDER: scopus
DOI/URL:
Notes: Review -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors